Bortezomib & Mycophenolate mofetil

Phase 2
Systemic Sclerosis ILD
Intervention Type:
Intravenous (IV) Injection
Funder Type:
Organization | University

Drug Details

Bortezomib is an FDA approved therapy for the treatment of multiple myeloma and other malignancies. 

Mycophenolate mofetil (CellCept or Myfortic) belongs to a class of medications known as immunosuppressives. This medication was used originally in the management of patients with organ transplants, but is now recommended in the treatment of some autoimmune diseases such as SSc.

Study Purpose

The purpose of this study is to look at whether bortezomib, mycophenolate or the combination of both is better to treat scarring of the lung caused by Systemic Sclerosis.

This drug has no clinical trials actively recruiting patients at this time.